Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
